Today: 19 January 2026
Subscribe
Browse Category

Pharma News News 9 December 2025 - 16 December 2025

Amgen Stock (AMGN) News Today, Dec. 16, 2025: Dividend Boost, FDA Wins, Analyst Targets, and Key 2026 Catalysts

Amgen Stock (AMGN) News Today, Dec. 16, 2025: Dividend Boost, FDA Wins, Analyst Targets, and Key 2026 Catalysts

Amgen Inc. (NASDAQ: AMGN) is in focus on December 16, 2025, as investors weigh a fresh dividend raise, recent regulatory momentum, and a pipeline narrative that stretches from cardiovascular outcomes to the high-stakes obesity race. As of Dec. 16, 2025 (18:00 UTC), Amgen shares traded around $324.36, slightly lower on the day, with an intraday range roughly between $323.05 and…
16 December 2025
····
Johnson & Johnson Stock After Hours (Dec. 15, 2025): JNJ Rises on FDA Priority Voucher — What to Know Before Tuesday’s Open

Johnson & Johnson Stock After Hours (Dec. 15, 2025): JNJ Rises on FDA Priority Voucher — What to Know Before Tuesday’s Open

Johnson & Johnson (NYSE: JNJ) shares finished Monday, December 15, 2025 higher and held modest gains in extended trading — a notable showing for a defensive blue chip as investors brace for a data-heavy week and shifting rate expectations. JNJ closed at $214.17 (+1.22%) and traded around $214.99 in after-hours (+0.38%) as of 7:15 p.m. ET. During the regular session,…
16 December 2025
····
Amicus Therapeutics (FOLD) Stock News Today: DMX-200 Trial Milestone, 52-Week High Momentum, and Analyst Forecasts (Dec. 15, 2025)

Amicus Therapeutics (FOLD) Stock News Today: DMX-200 Trial Milestone, 52-Week High Momentum, and Analyst Forecasts (Dec. 15, 2025)

Amicus Therapeutics, Inc. (Nasdaq: FOLD) is back on investors’ radar as the rare-disease biotech extends a strong 2025 run—helped by a milestone quarter of GAAP profitability, expanding global launches for its Pompe franchise, and fresh news tied to a Phase 3 kidney-disease program it licensed earlier this year. On Monday, December 15, 2025, Amicus shares traded around $10.93 intraday after…
15 December 2025
···
GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead GSK plc stock (LSE: GSK, NYSE: GSK) is ending 2025 with a rare “cluster” of market-moving catalysts packed into the same two-week window: fresh U.S. regulatory momentum for a new antibiotic, European regulatory backing for multiple respiratory…
15 December 2025
···
Corona Remedies Share Price Today (15 Dec 2025): Pharma Stock Debuts at 38% Premium After ₹655-Crore IPO — Latest News, Forecasts, Valuation and Analyst Views

Corona Remedies Share Price Today (15 Dec 2025): Pharma Stock Debuts at 38% Premium After ₹655-Crore IPO — Latest News, Forecasts, Valuation and Analyst Views

New Delhi / Mumbai, December 15, 2025 — Corona Remedies Limited, the Ahmedabad-headquartered branded pharmaceutical formulations company (not the beer), hit Dalal Street with a headline-worthy debut on Monday: the stock listed at a 38%+ premium to its IPO price, quickly becoming one of the most-watched new names in India’s healthcare space. Business Standard Below is a consolidated, publication-ready roundup…
15 December 2025
····
Merck stock (MRK): News, dividend date, Keytruda updates and analyst forecasts to watch before the U.S. market opens Dec. 15, 2025

Merck stock (MRK): News, dividend date, Keytruda updates and analyst forecasts to watch before the U.S. market opens Dec. 15, 2025

Merck & Co., Inc. (NYSE: MRK) heads into Monday’s U.S. session (December 15, 2025) with investors juggling a mix of near-term headlines and long-term franchise questions: a fresh dividend “reset” that makes Dec. 15 an important calendar day, ongoing scrutiny around RSV prevention products, and high-stakes execution on the company’s plan to diversify beyond Keytruda ahead of the drug’s expected…
14 December 2025
····
Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune, Inc. (NASDAQ: ALT) is back on many biotech watchlists as investors weigh two competing forces: a near-term clinical and regulatory catalyst calendar for pemvidutide (the company’s lead asset) and a capital-raising backdrop that can quickly change the stock’s risk/reward profile. On Friday, Dec. 12, 2025 , ALT shares are trading in a volatility-heavy tape where options flow, analyst targets,…
12 December 2025
····
Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus

Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus

Dec. 12, 2025 — Bristol-Myers Squibb Company (NYSE: BMY ) is back in the spotlight heading into year-end as investors weigh a fresh dividend increase, meaningful regulatory milestones in oncology, and a pipeline that has delivered both high-profile wins and frustrating setbacks in 2025. By mid-day Friday, BMY stock traded around $52.50, up roughly 2.5% , reflecting a market that’s…
12 December 2025
····
Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) stock is on a tear. On 11 December 2025, shares surged to a new all‑time high after the company reported encouraging mid‑stage data in Prader‑Willi syndrome (PWS) and investors refocused on a growing obesity franchise built around its melanocortin‑4 receptor (MC4R) agonist, IMCIVREE (setmelanotide). Investing As of Thursday morning, RYTM was trading around $121 per…
11 December 2025
···
Eli Lilly (LLY) After Hours: How a $6 Billion Bet, Fresh Oncology Data and Fed Rate Cut Set the Stage for December 11, 2025

Eli Lilly (LLY) After Hours: How a $6 Billion Bet, Fresh Oncology Data and Fed Rate Cut Set the Stage for December 11, 2025

Eli Lilly and Company (NYSE: LLY) closed just under the psychologically important $1,000 mark on Wednesday, December 10, 2025, then ticked slightly higher in after‑hours trading as investors digested a wave of company‑specific news against a backdrop of a fresh Federal Reserve rate cut. Yahoo Finance Below is what happened after the bell on Dec. 10 and what traders and…
11 December 2025
···
Ascendis Pharma (ASND) Stock Slides After Q3 Miss and FDA Delay – What Investors Need to Know on December 9, 2025

Ascendis Pharma (ASND) Stock Slides After Q3 Miss and FDA Delay – What Investors Need to Know on December 9, 2025

Ascendis Pharma A/S (NASDAQ: ASND) is back in the spotlight on December 9, 2025, after its share price slipped again while Wall Street continues to project hefty upside and label the name a “Buy” or “Strong Buy.” The Danish biotech, known for its TransCon long-acting prodrug platform and endocrine rare disease franchise, is wrestling with three forces at once: Let’s…
9 December 2025
····
Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook

Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook

Eli Lilly and Company (NYSE: LLY) is once again in the spotlight. As of early trading on December 9, 2025, Eli Lilly stock is hovering around $997 per share, roughly 10% below its late‑November all‑time high but still up about 30% year to date and about 25% over the past 12 months. FinanceCharts Today’s story is about more than the…
9 December 2025
···
1 … 3 4 5 6 7 … 10

Stock Market Today

  • XBM Stock Analysis and AI-Generated Trading Signals for iShares Metals ETF
    January 19, 2026, 12:53 PM EST. On January 19, 2026, the iShares S&P/TSX Global Base Metals Index ETF (XBM:CA) received mixed AI-generated ratings. The near-term outlook is rated Strong, signaling potential short-term gains. However, both mid-term and long-term ratings are Weak, indicating cautious sentiment ahead. The suggested trading plan advises a buy near $20.96 with a stop loss at $20.86 to limit downside risk. No short-selling recommendations are presently offered. These signals stem from AI analysis incorporating market data up to the time of update, providing traders with timely insights on XBM's performance prospects.
Go toTop